US 12,214,042 B2
Method for stabilization and delivery of therapeutic molecules
Nayan Patel, La Habra, CA (US); and Chinh Tran, La Habra, CA (US)
Assigned to Nayan Patel, La Habra, CA (US)
Filed by Nayan Patel, La Habra, CA (US); and Chinh Tran, La Habra, CA (US)
Filed on Feb. 8, 2023, as Appl. No. 18/166,412.
Application 14/275,625 is a division of application No. 13/526,332, filed on Jun. 18, 2012, abandoned.
Application 18/166,412 is a continuation of application No. 17/737,424, filed on May 5, 2022, granted, now 11,602,564.
Application 17/737,424 is a continuation of application No. 16/435,306, filed on Jun. 7, 2019, granted, now 11,351,262, issued on Jun. 7, 2022.
Application 16/435,306 is a continuation of application No. 15/240,871, filed on Aug. 18, 2016, granted, now 10,328,152, issued on Jun. 25, 2019.
Application 15/240,871 is a continuation in part of application No. 14/275,625, filed on May 12, 2014, abandoned.
Claims priority of provisional application 61/497,869, filed on Jun. 16, 2011.
Prior Publication US 2023/0293697 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/40 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 31/198 (2006.01); A61K 31/34 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/385 (2006.01); A61K 31/724 (2006.01); A61K 38/06 (2006.01); A61K 38/16 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/42 (2017.01)
CPC A61K 47/40 (2013.01) [A61K 9/0014 (2013.01); A61K 9/1617 (2013.01); A61K 31/198 (2013.01); A61K 31/34 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/385 (2013.01); A61K 31/724 (2013.01); A61K 38/063 (2013.01); A61K 38/16 (2013.01); A61K 47/186 (2013.01); A61K 47/22 (2013.01); A61K 47/42 (2013.01)] 19 Claims
 
1. A composition comprising:
an inclusion complex comprising reduced glutathione and gamma cyclodextrin;
wherein the reduced glutathione is non-esterified, non-acetylated, and non-fatty acid attached;
wherein the molar ratio of the reduced glutathione to the gamma cyclodextrin is between about 4:1 and 13:1;
wherein ultrasonic waves nanonize the pH stabilized inclusion complex into nanoparticles;
wherein the nanoparticles have a particle size range between 2 to 160 nanometers; and
wherein the composition is configured for topical administration.